174 results about "Haemophilus influenzae" patented technology

The invention discloses a kit for quickly detecting 15 pneumonia pathogenic bacteria. The kit can detect streptococcus pneumoniae, staphylococcus aureus, haemophilus influenzae, mycoplasma pneumoniae, pseudomonas aeruginosa, baumanii, enterococcus faecalis, enterococcus faecium, klebsiella pneumoniae, escherichia coli, enterobacter cloacae, stenotrophomonas maltophilia, burkholderia cepacia, legionella pneumophila and chlamydia pneumoniae which cover clinically common pneumonia pathogenic bacteria difficult to culture. 16S rDNA and specific gene sequences corresponding to the pneumonia pathogenic bacteria are detected by combining gene chips with multiple asymmetric PCR reactions, and the categories of the bacteria in a to-be-detected sample are identified in genus and species. The kit makes up for the defect that current clinical detection of pneumonia pathogenic bacteria is not in time or comprehensive and a novel detection means for early diagnosis and early treatment of patients suffering from pneumonia is provided.

The present invention relates to the large scale in vivo synthesis of globosides oligosaccharides; especially globotriose, globotetraose and globopentaose, which are the carbohydrate portions of globotriosylceramide (Gb3Cer), globotetraosylceramide (Gb4Cer) and globopentaosylceramide (Gb5Cer) respectively. It also relates to high yield production of potential anticancer vaccines of the globo-series glycosphingolipids, including the Globo-H. It also relates to the use of the glycosyltransferase encoded by the lgtD gene from Haemophilus influenzae as a beta1,3 galactosyl transferase to catalyze the transfer of a galactose moiety from UDP-Gal to an acceptor bearing the terminal non reducing structure GalNAcbeta-3-R to form the Galbeta-3GalNAcbeta-3-R structure

A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.

The invention provides a pathogen inspection reagent, and concretely discloses a primer probe combination and a kit for combined inspection of 15 kinds of respiratory tract infection pathogens. By aiming at specific target sequences of the gene sequence conserved region of klebsiella pneumoniae, haemophilus influenzae, streptococcus pyogenes, staphylococcus aureus, escherichia coli, chlamydia pneumoniae, mycobacterium tuberculosis, stenotrophomonas maltophilia, baumanii, mycoplasma pneumoniae, enterococcus faecalis, ligionella pneumohpillia, streptococcus pneumoniae, bacillus pyocyaneus and mycobacterium abscessus, primers and probes which do not have mutual crossed reaction are designed, so that the problem that detection probes of different pathogens can easily generate mutual influenceor interference is solved; the combination and matching of different primers and probes are ensured; the goal of simultaneously performing efficient specific inspection at the same temperature can also be achieved.

The invention discloses a method for detecting infectious disease pathogens possibly existing in a biological sample. The infectious disease pathogens comprise chlamydia pneumoniae, haemophilus influenzae, mycoplasma pneumoniae, pneumoniae streptococcus and legionella pneumophila. The method comprises the following steps: expanding nucleic acid fragments of the biological sample, and detecting the nucleic acid fragments by using a probe. The invention also provides primers used for expanding and the probe used for detection. The invention also provides a kit comprising the primers. The method has the advantages of high sensitivity, strong specificity, simple operation and wide sample range, can simultaneously detect various infectious disease pathogens, and is suitable for early diagnosis of respiratory infectious diseases.

The present invention discloses a Haemophilus influenzac type B polysaccharide conjugate vaccine preparation method, which comprises: A, preparing a Haemophilus influenzac type B polysaccharide extract (PRP), adopting ultrapure water or water for injection to dissolve the PRP polysaccharide at a room temperature until achieving a concentration of 20 mg/ml, adding CDAP according to a mass ratio of PRP to CDAP of 1, maintaining for 1.5 min, adjusting the pH value to 9.5 with 0.3 M NaOH, maintaining for 3 min, adding a solid ADH according to a mass ratio of ADH to the PRP polysaccharide of 4:1, adjusting the pH value to 9.5 with 0.3 M NaOH, maintaining for 1 h, and carrying out dialysis at a temperature of 2-8 DEG C with 0.2 M NaCl; and B, mixing the obtained PRP-AH and a 20 mg/ml TT solution according to a mass ratio of 1:2, adjusting the pH value to 5.0 with 0.1 M HCL, adding a solid EDAC according to a mass ratio of EDAC to PRP of 10:1, maintaining the pH value of 5.0 for 60 min at a room temperature, adjusting the pH value to 7.5 with 0.3 M NaOH, and carrying out a reaction for 30 min.

The present invention relates to a combination vaccine comprising a mixture of antigens for protection against diseases such as diphtheria, tetanus, acellular pertussis, and infections caused by Haemophilus influenzae and polio viruses. The present invention also relates to inclusion of antigens for protection against infections caused Hepatitis virus and other pathogens, such that administration of the vaccine can simultaneously immunize a subject against more than one pathogen. The invention in particular relates to a fully liquid stable combination vaccine comprising the antigens as indicated above and the methods for manufacturing the same.

The invention relates to an oligonucleotide sequence combination for specifically detecting existence of streptococcus pneumoniae and haemophilus influenzae nucleic acids in samples by adopting fluorescent PCR (polymerase chain reaction) technology and a kit comprising the combination. The kit can sensitively detect and identify the streptococcus pneumoniae and haemophilus influenzae nucleic acids in the samples, has limits of detection of 20 copies per reaction system and has important application values in the fields such as disease surveillance and clinical diagnosis.

Process for conjugation of bacterial saccharides including Streptococcus pneumoniae and Haemophilus influenzae saccharides by reductive amination are provided herein.

The present invention provides a method of detecting Haemophilus influenzae, which enables accurate and rapid detection of H. influenzae, a primer set for detecting H. influenzae, and a kit for detecting H. influenzae.

Nucleic acid amplification is carried out using the DNA of H. influenzae as a template, and also using the LAMP primers as shown in SEQ ID NOS: 1 to 5 given as examples of the present invention. Thus, the presence or absence of the amplified product is detected. When primers having sequences that are complementary to the sequences as shown in SEQ ID NOS: 1 to 5 are used, such primers are excellent in terms of detection sensitivity and promptness of detection, as well as specificity. In addition, as another example of the present invention, nucleic acid amplification is carried out using LAMP primers as shown in SEQ ID NOS: 43 to 47, and the presence or absence of the amplified product is detected. Thereby, H. influenzae Type b can be distinguished from other capsular serotype and non-encapsulated type H. influenzae, and it can be detected rapidly, simply, and accurately.

The invention discloses a method and a kit for performing quick co-detection on anti-human Hi (Haemophilus influenzae) IgM (Immunoglobulin M) and IgG (Immunoglobulin G) antibodies based on magnetic separation and multi-color quantum dot labeling. The kit consists of anti-human Hi antibody capturing nano magnetic beads with an anti-human Hi IgM and IgG antibody gathering function, anti-human IgM and IgG antibody nano probes labeled by multi-color quantum dots, quality control substances and a PBST buffering solution, wherein the quality control substances comprise a positive quality control substance and a negative quality control substance; the positive quality control substance is serum, in which anti-human Hi IgM and IgG antibodies of human Hi infected people are respectively positive; the negative quality control substance is serum, in which anti-human Hi IgM and IgG are respectively negative. The kit and the method have the advantages of simplicity, quickness and high sensitivity, and can be used for carrying out synchronous detection on the anti-human Hi IgM and IgG antibodies.

The invention relates to a ceftizoxime sodium crystalline hydrate and a preparation method and application thereof. The ceftizoxime sodium crystalline hydrate has high storage stability, and is suitable for preparing medicaments for treating or preventing diseases such as infection of respiratory systems, liver and biliary systems, five sense organs and urinary tracts of human bodes or animals, infection of abdominal cavity, infection of pelvic cavity, ichorrhemia, infection of skin tissues, and infection of bones and joint caused by gram positive or negative bacteria, meningitis caused by streptococcus pneumonia or haemophilus influenza, and simple gonorrhea.

The invention provides lavender cellulose fiber. The lavender cellulose fiber is characterized in that the content of a lavender extract is 6.6-10.0%, the dry breaking strength is 3.7-4.5 cN/dtex andthe wet breaking strength is 2.5-3.2 cN/dtex. The invention further provides a preparation method for the lavender cellulose fiber. The preparation method comprises the steps of preparing a compound coordinating agent, preparing a modifying agent, carrying out mixing, carrying out spinning and carrying out after-treatment. According to the lavender cellulose fiber and the preparation method thereof, after a pure textile prepared from the lavender cellulose fiber is washed 20 times, the bacteriostasis rate of MRSA (Methicillin-resistant Staphylococcus aureus) is 82-93%, the bacteriostasis rateof enterococcus faecalis is 93-98%, the bacteriostasis rate of streptococcus pyogenes is 72-90%, and the bacteriostasis rate of haemophilus influenzae is 75-83%; and the lavender component is added into the fiber, so that the prepared fiber also has a part of functions of the fiber and has the effects of promoting cell regeneration, accelerating wound healing and ameliorating acne, abscess and eczema.